Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Construction in Progress (2018 - 2021)

Historic Construction in Progress for Ascendis Pharma A (ASND) over the last 4 years, with Q4 2021 value amounting to $2173.5.

  • Ascendis Pharma A's Construction in Progress fell 2073.91% to $2173.5 in Q4 2021 from the same period last year, while for Dec 2021 it was $2173.5, marking a year-over-year decrease of 2073.91%. This contributed to the annual value of $2173.5 for FY2021, which is 2073.91% down from last year.
  • Ascendis Pharma A's Construction in Progress amounted to $2173.5 in Q4 2021, which was down 2073.91% from $2742.3 recorded in Q4 2020.
  • Ascendis Pharma A's 5-year Construction in Progress high stood at $3.0 million for Q4 2019, and its period low was $2173.5 during Q4 2021.
  • Over the past 4 years, Ascendis Pharma A's median Construction in Progress value was $115510.8 (recorded in 2020), while the average stood at $805447.9.
  • As far as peak fluctuations go, Ascendis Pharma A's Construction in Progress skyrocketed by 120918.44% in 2019, and later crashed by 9990.82% in 2020.
  • Over the past 4 years, Ascendis Pharma A's Construction in Progress (Quarter) stood at $228279.3 in 2018, then skyrocketed by 1209.18% to $3.0 million in 2019, then plummeted by 99.91% to $2742.3 in 2020, then fell by 20.74% to $2173.5 in 2021.
  • Its last three reported values are $2173.5 in Q4 2021, $2742.3 for Q4 2020, and $3.0 million during Q4 2019.